Resinco CP (RIN.TO) - Neustart mit langfristiger Erfolgsaussicht (Seite 61)
eröffnet am 01.12.09 20:52:14 von
neuester Beitrag 22.06.22 14:22:44 von
neuester Beitrag 22.06.22 14:22:44 von
Beiträge: 2.076
ID: 1.154.579
ID: 1.154.579
Aufrufe heute: 0
Gesamt: 238.925
Gesamt: 238.925
Aktive User: 0
ISIN: CA73108T1049 · WKN: A3D9T1 · Symbol: RSCZF
0,0006
USD
0,00 %
0,0000 USD
Letzter Kurs 23.05.24 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 25,00 | +50,33 | |
| 1,9800 | +33,78 | |
| 7,0488 | +26,07 | |
| 5,8039 | +22,96 | |
| 55,50 | +17,09 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,2000 | -10,64 | |
| 1,4500 | -13,69 | |
| 21,055 | -13,87 | |
| 7,0000 | -17,65 | |
| 0,7500 | -37,50 |
Beitrag zu dieser Diskussion schreiben
Feedback
schaut gut aus
Antwort auf Beitrag Nr.: 59.206.817 von erti am 13.11.18 18:24:07
Resinco arranges $4-million private placement
2018-11-09 18:35 ET - News Release
Mr. Alexander Somjen reports
RESINCO CAPITAL PARTNERS ANNOUNCES PRIVATE PLACEMENT
Resinco Capital Partners Inc. has arranged a non-brokered private placement of up to 16 million subscription receipts of the company at an issue price of 25 cents per subscription receipt, for gross proceeds of up to $4-million. The private placement proceeds will be immediately available to the company on closing. Each subscription receipt will automatically convert into one common share of the company on the earlier of: (i) the expiry of applicable hold periods; (ii) the election by the subscriber to convert the subscription receipts; (iii) this issuance of a (final) receipt for a prospectus qualifying the issuance of the underlying common shares; and (iv) the date the company completes a corporate transaction that includes the conversion of the subscription receipts into common shares of the company, free from further resale restrictions.
In connection with the private placement, the company may pay finders' fees within the allowable limits of the policies of the Canadian Securities Exchange.
All securities issued in connection with the private placement are subject to a prescribed four-month hold and restricted trading period. The net proceeds of the private placement will be used to finance further investments by the company pursuant to its investment mandate and for general working capital.
About Resinco Capital Partners Inc.
Resinco Capital Partners is a global investment company which specializes in providing early-stage financing to private and public companies, as well as medical marijuana pharmaceutical companies. The company engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early-stage investment opportunities that adequately reflect the risk profile.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aRIN-2682…
Resinco arranges $4-million private placement
2018-11-09 18:35 ET - News Release
Mr. Alexander Somjen reports
RESINCO CAPITAL PARTNERS ANNOUNCES PRIVATE PLACEMENT
Resinco Capital Partners Inc. has arranged a non-brokered private placement of up to 16 million subscription receipts of the company at an issue price of 25 cents per subscription receipt, for gross proceeds of up to $4-million. The private placement proceeds will be immediately available to the company on closing. Each subscription receipt will automatically convert into one common share of the company on the earlier of: (i) the expiry of applicable hold periods; (ii) the election by the subscriber to convert the subscription receipts; (iii) this issuance of a (final) receipt for a prospectus qualifying the issuance of the underlying common shares; and (iv) the date the company completes a corporate transaction that includes the conversion of the subscription receipts into common shares of the company, free from further resale restrictions.
In connection with the private placement, the company may pay finders' fees within the allowable limits of the policies of the Canadian Securities Exchange.
All securities issued in connection with the private placement are subject to a prescribed four-month hold and restricted trading period. The net proceeds of the private placement will be used to finance further investments by the company pursuant to its investment mandate and for general working capital.
About Resinco Capital Partners Inc.
Resinco Capital Partners is a global investment company which specializes in providing early-stage financing to private and public companies, as well as medical marijuana pharmaceutical companies. The company engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early-stage investment opportunities that adequately reflect the risk profile.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aRIN-2682…
der kurs steigt . was ist los .... ?
Trading Spotlight
Antwort auf Beitrag Nr.: 38.490.053 von Hanfy am 01.12.09 20:52:14Neustart mit langfristiger Erfolgsaussicht
_____________________________
Für WIE gut halten Sie Diese Analyse?
_____________________________
Für WIE gut halten Sie Diese Analyse?
gut gut , viel. holt man hir ja noch was raus .
Resinco Capital Partners Makes First Investment in Cannabis Pharma Sector
VANCOUVER, British Columbia, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Resinco Capital Partners Inc. (CSE:RIN) (the “Company” or “Resinco”) announces that it has made an investment in Toronto, Ontario and Palo Alto, California based Cannabis Pharma company Katexco Pharmaceuticals Corp.
The Company has now made its first investment in the Cannabis Pharma Sector with its investment in Katexco Pharmaceuticals. Katexco is led by a world class team of scientists that come from Stanford University in California. Resinco is excited to pursue further investments in the Cannabis Pharma Sector in the near future.
Prof. Lawrence Steinman, Chairman and Co-Founder of Katexco said, “We are extremely pleased to welcome Resinco Capital Partners as investors in Katexco.”
Alexander Somjen, President and CEO of Resinco said, “After announcing our decision to pursue investment opportunities in the growing Cannabis Pharma sector, Katexco made sense as our first Cannabis Pharma investment. With their world class team, Katexco is working on life changing treatments.”
About Resinco Capital Partners
Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies focused on the growing Cannabis Pharma Sector. The Company engages in new, early stage investment opportunities in previously underdeveloped life sciences and biotech companies which a specific focus on Cannabis Pharma, obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
Website:
www.resincocp.com
About Katexco Pharmaceuticals Corp
Katexco Pharmaceuticals is a medical cannabis company developing innovative, orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. Formed by Dr. Jonathan Rothbard and Professor Lawrence Steinman, the Company is developing the world’s first drug to exploit a key receptor on immune cells in the brain with the ability to treat inflammatory diseases.
Website:
https://katexcopharma.com/
Medical Cannabis Market Opportunity
The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Already over 1.2 million people use Medical Marijuana for medical problems.
Growth for its use is underpinned by numerous factors such as legislation permitting its use for medicinal benefits. Increasing research in the medical field has shown marijuana’s benefits in suppressing vomiting and nausea, pain relief, whilst also generating a growing number therapeutic applications for inflammation, HIV/AIDS, cancer, multiple sclerosis, epilepsy, Huntington’s disease and Parkinson’s disease.
On behalf of the Board of Directors
RESINCO CAPITAL PARTNERS INC.:
Mr. Alexander Somjen, CEO
For more information, please contact
Theo van der Linde- 604.336.3196
https://web.tmxmoney.com/article.php?newsid=8836377725463443…
Resinco Capital Partners Completes Investment in Cannabis Pharma Company ReFormation Pharmaceuticals Corp.
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Resinco Capital Partners Inc. (CSE:RIN) (the “Company” or “Resinco”) announces that it has completed an investment in Toronto, ON and Oxford, UK based Cannabis Pharma Company, ReFormation Pharmaceuticals Corp.(“ReFormation”) through the acquisition of 49% of ReFormation’s outstanding shares.
Resinco will issue 27,000,000 newly issued shares to shareholders of ReFormation for its 49% interest. Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.
Resinco has an option to make further investments in ReFormation, subject to certain conditions.
ReFormation Pharmaceuticals Corp
ReFormation Pharmaceuticals Corp is a Medical Marijuana Pharmaceutical company headquartered in Toronto, ON with its Research and Development team at the University of Oxford. The company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in class therapeutic. The Company has identified a molecule that primes the body’s own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company’s research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and CSO, Professor Jagdeep Nanchahal, of the University of Oxford.
Website:
https://www.reformationpharma.com/
ReFormation addresses numerous unmet clinical needs and focuses on treatments for:
Myocardial infarction (MI) - Cardiovascular disease is the leading cause of mortality in the West, in the USA a person is estimated to suffer a myocardial infarction (MI) every 40 seconds.i
Type 1 Diabetes - Type 1 diabetes affects approximately 1 in 300 people under the age of 18 years in the USA and accounts for 10% of all causes of diabetes.ii
Parkinson’s Disease - Parkinson’s disease is the second commonest neurodegenerative disorder, will affect nearly 1 million people in the USA by 2020 and is estimated to increase to 1.24 million individuals by 2030.iii
Liver Injury - Approximately 60% of patients with NAFLD go on to develop non-alcoholic steatohepatitis (NASH) and 25% of these develop liver cirrhosis, equating to 1.5-2% of the total population.iv
Stem Cell Opportunity
The Global Stem Cell Market was worth $5.17 Billion USD in 2017 and it is estimated to grow to $9.03 Billion USD by 2023 with a CAGR of 9.74% between 2017 and 2023.v
Stem cells are responsible for the repair and healing of all tissues. Whilst stem cell therapy has now become the standard of care for many blood disorders, despite the perceived promise, media hype and huge investment, cellular therapy for solid organs has not yielded the anticipated benefits. Stem cells change when in culture and very few engraft into the scarred and inflamed tissue bed.
Further, personalized therapy would be prohibitively expensive and beyond the means of all healthcare systems given the increasing and overwhelming burden of the many degenerative diseases due to our aging population.
Medical Cannabis Market Opportunity
The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Already over 1.2 million people use Medical Marijuana for medical problems.vi
Growth for its use is underpinned by numerous factors such as legislation permitting its use for medicinal benefits. Increasing research in the medical field has shown marijuana’s benefits in suppressing vomiting and nausea, pain relief, whilst also generating a growing number therapeutic applications for inflammation, HIV/AIDS, cancer, multiple sclerosis, epilepsy, Huntington’s disease and Parkinson’s disease.
Prof. Jagdeep Nanchahal, CEO & CSO of ReFormation, said, “We are thrilled to have received this investment from Resinco, which speaks volumes of the Cannabis Pharma space as a whole, and our groundbreaking work within it. We are delighted to have them by our side as we work on developing life changing therapeutics.”
Alexander Somjen, President and CEO of Resinco, said, “ReFormation is working on cutting edge Cannabis Pharma therapies overseen by some of the brightest minds in the pharmaceutical industry. This is a very exciting opportunity for Resinco and its shareholders.”
About Resinco Capital Partners
Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical marijuana pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.
Website:
www.resincocp.com
On behalf of the Board of Directors
RESINCO CAPITAL PARTNERS INC.:
Mr. Alexander Somjen, CEO
For more information, please contact
Alexander Somjen - 647-362-8998;102
https://web.tmxmoney.com/article.php?newsid=5330314611720110…
VANCOUVER, British Columbia, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Resinco Capital Partners Inc. (CSE:RIN) (the “Company” or “Resinco”) announces that it has made an investment in Toronto, Ontario and Palo Alto, California based Cannabis Pharma company Katexco Pharmaceuticals Corp.
The Company has now made its first investment in the Cannabis Pharma Sector with its investment in Katexco Pharmaceuticals. Katexco is led by a world class team of scientists that come from Stanford University in California. Resinco is excited to pursue further investments in the Cannabis Pharma Sector in the near future.
Prof. Lawrence Steinman, Chairman and Co-Founder of Katexco said, “We are extremely pleased to welcome Resinco Capital Partners as investors in Katexco.”
Alexander Somjen, President and CEO of Resinco said, “After announcing our decision to pursue investment opportunities in the growing Cannabis Pharma sector, Katexco made sense as our first Cannabis Pharma investment. With their world class team, Katexco is working on life changing treatments.”
About Resinco Capital Partners
Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies focused on the growing Cannabis Pharma Sector. The Company engages in new, early stage investment opportunities in previously underdeveloped life sciences and biotech companies which a specific focus on Cannabis Pharma, obtaining positions in early stage investment opportunities that adequately reflect the risk profile.
Website:
www.resincocp.com
About Katexco Pharmaceuticals Corp
Katexco Pharmaceuticals is a medical cannabis company developing innovative, orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. Formed by Dr. Jonathan Rothbard and Professor Lawrence Steinman, the Company is developing the world’s first drug to exploit a key receptor on immune cells in the brain with the ability to treat inflammatory diseases.
Website:
https://katexcopharma.com/
Medical Cannabis Market Opportunity
The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Already over 1.2 million people use Medical Marijuana for medical problems.
Growth for its use is underpinned by numerous factors such as legislation permitting its use for medicinal benefits. Increasing research in the medical field has shown marijuana’s benefits in suppressing vomiting and nausea, pain relief, whilst also generating a growing number therapeutic applications for inflammation, HIV/AIDS, cancer, multiple sclerosis, epilepsy, Huntington’s disease and Parkinson’s disease.
On behalf of the Board of Directors
RESINCO CAPITAL PARTNERS INC.:
Mr. Alexander Somjen, CEO
For more information, please contact
Theo van der Linde- 604.336.3196
https://web.tmxmoney.com/article.php?newsid=8836377725463443…
Resinco Capital Partners Completes Investment in Cannabis Pharma Company ReFormation Pharmaceuticals Corp.
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Resinco Capital Partners Inc. (CSE:RIN) (the “Company” or “Resinco”) announces that it has completed an investment in Toronto, ON and Oxford, UK based Cannabis Pharma Company, ReFormation Pharmaceuticals Corp.(“ReFormation”) through the acquisition of 49% of ReFormation’s outstanding shares.
Resinco will issue 27,000,000 newly issued shares to shareholders of ReFormation for its 49% interest. Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.
Resinco has an option to make further investments in ReFormation, subject to certain conditions.
ReFormation Pharmaceuticals Corp
ReFormation Pharmaceuticals Corp is a Medical Marijuana Pharmaceutical company headquartered in Toronto, ON with its Research and Development team at the University of Oxford. The company is focused on an innovative approach to repair vital organs by combining cannabinoids and an endogenous trigger of repair (HMGB1). ReFormation is based on disruptive technology which will deliver a first in class therapeutic. The Company has identified a molecule that primes the body’s own stem cells from a diverse range of tissues to accelerate repair and regeneration following acute or chronic injury. The Company’s research pipeline will deliver further IP based on composition of matter and has a comprehensive work package of testing in animal models of diseases where no comparative treatment exists. ReFormation Pharmaceuticals is led by world class scientist, CEO and CSO, Professor Jagdeep Nanchahal, of the University of Oxford.
Website:
https://www.reformationpharma.com/
ReFormation addresses numerous unmet clinical needs and focuses on treatments for:
Myocardial infarction (MI) - Cardiovascular disease is the leading cause of mortality in the West, in the USA a person is estimated to suffer a myocardial infarction (MI) every 40 seconds.i
Type 1 Diabetes - Type 1 diabetes affects approximately 1 in 300 people under the age of 18 years in the USA and accounts for 10% of all causes of diabetes.ii
Parkinson’s Disease - Parkinson’s disease is the second commonest neurodegenerative disorder, will affect nearly 1 million people in the USA by 2020 and is estimated to increase to 1.24 million individuals by 2030.iii
Liver Injury - Approximately 60% of patients with NAFLD go on to develop non-alcoholic steatohepatitis (NASH) and 25% of these develop liver cirrhosis, equating to 1.5-2% of the total population.iv
Stem Cell Opportunity
The Global Stem Cell Market was worth $5.17 Billion USD in 2017 and it is estimated to grow to $9.03 Billion USD by 2023 with a CAGR of 9.74% between 2017 and 2023.v
Stem cells are responsible for the repair and healing of all tissues. Whilst stem cell therapy has now become the standard of care for many blood disorders, despite the perceived promise, media hype and huge investment, cellular therapy for solid organs has not yielded the anticipated benefits. Stem cells change when in culture and very few engraft into the scarred and inflamed tissue bed.
Further, personalized therapy would be prohibitively expensive and beyond the means of all healthcare systems given the increasing and overwhelming burden of the many degenerative diseases due to our aging population.
Medical Cannabis Market Opportunity
The Medical Marijuana industry is rapidly growing. Currently the market is valued at $14.3B USD. It is estimated to reach a market value of $74.3B USD by 2027 at a projected CAGR of 17.9% from 2017 to 2027. Already over 1.2 million people use Medical Marijuana for medical problems.vi
Growth for its use is underpinned by numerous factors such as legislation permitting its use for medicinal benefits. Increasing research in the medical field has shown marijuana’s benefits in suppressing vomiting and nausea, pain relief, whilst also generating a growing number therapeutic applications for inflammation, HIV/AIDS, cancer, multiple sclerosis, epilepsy, Huntington’s disease and Parkinson’s disease.
Prof. Jagdeep Nanchahal, CEO & CSO of ReFormation, said, “We are thrilled to have received this investment from Resinco, which speaks volumes of the Cannabis Pharma space as a whole, and our groundbreaking work within it. We are delighted to have them by our side as we work on developing life changing therapeutics.”
Alexander Somjen, President and CEO of Resinco, said, “ReFormation is working on cutting edge Cannabis Pharma therapies overseen by some of the brightest minds in the pharmaceutical industry. This is a very exciting opportunity for Resinco and its shareholders.”
About Resinco Capital Partners
Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical marijuana pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.
Website:
www.resincocp.com
On behalf of the Board of Directors
RESINCO CAPITAL PARTNERS INC.:
Mr. Alexander Somjen, CEO
For more information, please contact
Alexander Somjen - 647-362-8998;102
https://web.tmxmoney.com/article.php?newsid=5330314611720110…
Global Blockchain Announces Initial Developments of Laser Crowdsale
After the commencement of the crowdsale for the Laser network on September 3, the Company has established firm interest from several institutional investors for participation in the sale. Further, partnership interest has been obtained with infrastructure providers for the operation of servicenodes on the Laser network. Individuals who have made submissions on Laser’s investors page will be contacted in the coming week to undertake the next steps in participating.
VANCOUVER, British Columbia, Sept. 09, 2018 (GLOBE NEWSWIRE) -- GLOBAL BLOCKCHAIN TECHNOLOGIES CORP. (CSE: BLOC, BLOC.CN, BLOC.CNX) (FSE: BWSP) (OTC: BLKCF) ("BLOC" or the "Company") announces that it has made several key developments since the Laser network’s crowdsale began on September 3rd. Over the course of the previous week, the Company began a roadshow in Europe to generate interest from investors and infrastructure providers. The result of this, combined with existing investor relations efforts, has resulted in confirmed interest from several institutional investors for participating in the crowdsale, as well as numerous infrastructure providers in the blockchain network space for operating servicenodes. Such providers were screened based on their technical resources, and their reputation for reliably providing similar services to others in the blockchain space. The roadshow will continue with stops in Asia, with many more prospective investors and infrastructure providers known in this region.
Starting this week, individuals who have registered their interest in the Laser network’s crowdsale on the Investors page will be contacted to begin the next steps for their investment.
The Laser network’s crowdsale is open to most investors worldwide, with the following three regional exceptions which may restrict some investors:
Investors from the United States must be accredited under the SEC’s accredited investor criteria;
Investors from Canada must be accredited under the accredited investor criteria of their province’s securities commission; and
Investors from the European Union must be accredited under the criteria set out in MiFID.
Further, for compliance, all investors will be required to provide both government-issued photo identification and proof of residency (property tax assessment, utility bill, etc.).
The crowdsale will lay the groundwork for the establishment of Laser Technologies Corp., as a governance organization for the Laser network until the network’s voting process moves onto the blockchain network. With the blockchain space still ripe for disruption by Laser’s SWIFT-like abilities, this organization will play a key role in ensuring that the Laser network and its stakeholders are given a robust offering of resources to promote the operation of the network in a sustainable and growth-oriented manner. Prospective investors who have not yet registered their interest, they may do so at www.laser.xyz/investors.
On behalf of the Company:
Shidan Gouran, President and CEO
info@globalblockchain.io
For more information, please contact:
IRTH Communications, LLC
ir@globalblockchain.io
800-689-8089
About Global Blockchain Technologies Corp.
The Company provides investors access to a basket of direct and indirect holdings within the blockchain space, managed by a team of industry pioneers and early adopters of all major cryptocurrencies.
The Company is focused on streamlining the currently arduous, lengthy, and complicated process that interested investors must undergo in order to gain exposure to the cryptocurrency space, with a view to becoming the first vertically-integrated originator and manager of top tier blockchains and digital currencies.
BLOC is listed on the Canadian Securities Exchange (“CSE”) and its common shares trade under the ticker symbol "BLOC." Additional information relating to BLOC is available on SEDAR at www.sedar.com, the CSE at www.theCSE.com, as well as on the Company's website at www.globalblockchain.io.
https://web.tmxmoney.com/article.php?newsid=5216031165104253…
After the commencement of the crowdsale for the Laser network on September 3, the Company has established firm interest from several institutional investors for participation in the sale. Further, partnership interest has been obtained with infrastructure providers for the operation of servicenodes on the Laser network. Individuals who have made submissions on Laser’s investors page will be contacted in the coming week to undertake the next steps in participating.
VANCOUVER, British Columbia, Sept. 09, 2018 (GLOBE NEWSWIRE) -- GLOBAL BLOCKCHAIN TECHNOLOGIES CORP. (CSE: BLOC, BLOC.CN, BLOC.CNX) (FSE: BWSP) (OTC: BLKCF) ("BLOC" or the "Company") announces that it has made several key developments since the Laser network’s crowdsale began on September 3rd. Over the course of the previous week, the Company began a roadshow in Europe to generate interest from investors and infrastructure providers. The result of this, combined with existing investor relations efforts, has resulted in confirmed interest from several institutional investors for participating in the crowdsale, as well as numerous infrastructure providers in the blockchain network space for operating servicenodes. Such providers were screened based on their technical resources, and their reputation for reliably providing similar services to others in the blockchain space. The roadshow will continue with stops in Asia, with many more prospective investors and infrastructure providers known in this region.
Starting this week, individuals who have registered their interest in the Laser network’s crowdsale on the Investors page will be contacted to begin the next steps for their investment.
The Laser network’s crowdsale is open to most investors worldwide, with the following three regional exceptions which may restrict some investors:
Investors from the United States must be accredited under the SEC’s accredited investor criteria;
Investors from Canada must be accredited under the accredited investor criteria of their province’s securities commission; and
Investors from the European Union must be accredited under the criteria set out in MiFID.
Further, for compliance, all investors will be required to provide both government-issued photo identification and proof of residency (property tax assessment, utility bill, etc.).
The crowdsale will lay the groundwork for the establishment of Laser Technologies Corp., as a governance organization for the Laser network until the network’s voting process moves onto the blockchain network. With the blockchain space still ripe for disruption by Laser’s SWIFT-like abilities, this organization will play a key role in ensuring that the Laser network and its stakeholders are given a robust offering of resources to promote the operation of the network in a sustainable and growth-oriented manner. Prospective investors who have not yet registered their interest, they may do so at www.laser.xyz/investors.
On behalf of the Company:
Shidan Gouran, President and CEO
info@globalblockchain.io
For more information, please contact:
IRTH Communications, LLC
ir@globalblockchain.io
800-689-8089
About Global Blockchain Technologies Corp.
The Company provides investors access to a basket of direct and indirect holdings within the blockchain space, managed by a team of industry pioneers and early adopters of all major cryptocurrencies.
The Company is focused on streamlining the currently arduous, lengthy, and complicated process that interested investors must undergo in order to gain exposure to the cryptocurrency space, with a view to becoming the first vertically-integrated originator and manager of top tier blockchains and digital currencies.
BLOC is listed on the Canadian Securities Exchange (“CSE”) and its common shares trade under the ticker symbol "BLOC." Additional information relating to BLOC is available on SEDAR at www.sedar.com, the CSE at www.theCSE.com, as well as on the Company's website at www.globalblockchain.io.
https://web.tmxmoney.com/article.php?newsid=5216031165104253…
danke hanfy .
Durchsuchen
